Fayen M, Goldman M B, Moulthrop M A, Luchins D J
Department of Psychiatry, Pritzker School of Medicine, University of Chicago, IL 60637.
Am J Psychiatry. 1988 Apr;145(4):483-6. doi: 10.1176/ajp.145.4.483.
Nine chronic schizophrenic patients being treated with high-potency antipsychotic medication and antiparkinsonian agents were enrolled in a double-blind, crossover trial comparing amantadine and trihexyphenidyl. Memory function was assessed with the Rey Auditory-Verbal Learning Test during each 6-week drug trial. The subjects performed significantly better while receiving amantadine. Examinations of computed tomographic studies of seven subjects revealed a significant inverse correlation between ventricle size and memory while they were taking trihexyphenidyl but not amantadine. This suggests that patients with underlying brain pathology may be particularly vulnerable to the memory-disrupting effects of anticholinergic agents.
九名正在接受高效抗精神病药物和抗帕金森病药物治疗的慢性精神分裂症患者参加了一项双盲交叉试验，比较金刚烷胺和苯海索。在每次为期6周的药物试验期间，用雷氏听觉词语学习测验评估记忆功能。受试者在服用金刚烷胺时表现明显更好。对七名受试者的计算机断层扫描研究显示，在服用苯海索而非金刚烷胺时，脑室大小与记忆之间存在显著的负相关。这表明，有潜在脑部病变的患者可能特别容易受到抗胆碱能药物记忆干扰作用的影响。
